clinical trial · NCT05644561
Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.·phase3·active not recruiting·n = 12
Generalized Myasthenia GravisgMGRavulizumab
brief summary
The primary purpose of this study is to characterize the pharmacokinetics and pharmacodynamics of treatment with ravulizumab intravenous infusion in pediatric participants with gMG.
started
Jun 24, 2023
primary completion
Jul 15, 2026
completion
Jun 30, 2028
last updated
Apr 17, 2026
official title
Phase 3, Open-label, Single-arm, Multicenter Study Evaluating Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants (6 to <18 Years) With Generalized Myasthenia Gravis (gMG)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol